Cargando…
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
IMPORTANCE: Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), wh...
Autores principales: | Vaishampayan, Ulka N., Heilbrun, Lance K., Monk, Paul, Tejwani, Sheela, Sonpavde, Guru, Hwang, Clara, Smith, Daryn, Jasti, Pallavi, Dobson, Kimberlee, Dickow, Brenda, Heath, Elisabeth I., Semaan, Louie, Cher, Michael L., Fontana, Joseph A., Chinni, Sreenivasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838941/ https://www.ncbi.nlm.nih.gov/pubmed/33496795 http://dx.doi.org/10.1001/jamanetworkopen.2020.34633 |
Ejemplares similares
-
TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
por: Semaan, Louie, et al.
Publicado: (2019) -
Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012) -
A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cells.
por: Sbrissa, Diego, et al.
Publicado: (2018) -
Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth
por: Govindarajan, Barani, et al.
Publicado: (2023) -
Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth
por: Govindarajan, Barani, et al.
Publicado: (2023)